[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,482
  • Shares Outstanding, K 57,912
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -120 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 338.72% (-48.12%)
  • Historical Volatility 298.72%
  • IV Percentile 92%
  • IV Rank 70.13%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 22) 4.24 (63.59%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 56,320
  • Volume Avg (30-Day) 9,965
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 139,998
  • Open Int (30-Day) 112,481
  • Expected Range 2.43 to 10.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 5
  • High Estimate $-0.47
  • Low Estimate $-0.63
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) -1.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.67 +17.74%
on 07/28/26
24.99 -73.31%
on 06/30/26
-17.13 (-71.97%)
since 06/29/26
3-Month
5.67 +17.74%
on 07/28/26
34.64 -80.74%
on 04/30/26
-25.79 (-79.45%)
since 04/29/26
52-Week
4.30 +55.12%
on 11/25/25
40.37 -83.48%
on 12/03/25
-0.07 (-1.04%)
since 07/29/25

Most Recent Stories

More News
Rosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR

NEW YORK , July 30, 2026 /PRNewswire/ --

CAPR : 6.67 (+1.52%)
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES , July 29, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...

CAPR : 6.67 (+1.52%)
Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Capricor investors lost 60% to 70% after FDA briefing documents challenged the Company's claims that Deramiocel demonstrated statistically significant benefits.

CAPR : 6.67 (+1.52%)
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met...

CAPR : 6.67 (+1.52%)
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor”...

CAPR : 6.67 (+1.52%)
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR ) investors concerning the Company’s...

CAPR : 6.67 (+1.52%)
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR)...

CAPR : 6.67 (+1.52%)
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR ) on behalf of investors concerning...

CAPR : 6.67 (+1.52%)
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided...

CAPR : 6.67 (+1.52%)
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE...

CAPR : 6.67 (+1.52%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 8.86
2nd Resistance Point 8.04
1st Resistance Point 7.30
Last Price 6.67
1st Support Level 5.75
2nd Support Level 4.93
3rd Support Level 4.20

See More

52-Week High 40.37
Fibonacci 61.8% 26.59
Fibonacci 50% 22.33
Fibonacci 38.2% 18.08
Last Price 6.67
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.